The FDA's Peter Marks says an upcoming guidance will address both the low- and higher-hanging fruit when it comes to scenarios for accelerated approval of gene therapies. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
